Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted EBIT Margin of 97.11% for Q1 2026, down 37.69% sequentially from 70.53% in Q4 2025, and down 1512.0% YoY from 6.88% in Q1 2025.
Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported EBIT Margin for 17 years, with the latest figure at 97.11% in Q1 2026.
- Quarterly EBIT Margin fell 1512.0% year-over-year to 97.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73.64% (down 3765.0% YoY) and the FY2025 annual result came in at 69.95%, down 4950.0% from the prior year.
- EBIT Margin fell to 97.11% in Q1 2026 per VNDA's latest filing, from 70.53% in the prior quarter.
- Over five years, EBIT Margin peaked at 10.28% in Q4 2022 and troughed at 97.11% in Q1 2026.
- A 5-year average of 28.57% and a median of 19.33% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2025: EBIT Margin jumped 1595 bps in 2023, then tumbled 6253 bps in 2025.
- Over 5 years, EBIT Margin stood at 10.28% in 2022, then plunged by 252 bps to 15.67% in 2023, then dropped by 23 bps to 19.33% in 2024, then sank by 265 bps to 70.53% in 2025, then tumbled by 38 bps to 97.11% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 97.11%, 70.53%, and 55.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -126.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -126.28% |
| Mar 31, 2026 | -97.11% |
| Dec 31, 2025 | -70.53% |
| Sep 30, 2025 | -55.61% |
| Jun 30, 2025 | -73.21% |
| Mar 31, 2025 | -81.99% |
| Dec 31, 2024 | -19.33% |
| Sep 30, 2024 | -23.08% |
| Jun 30, 2024 | -20.10% |
| Mar 31, 2024 | -19.46% |
| Dec 31, 2023 | -15.67% |
| Sep 30, 2023 | -15.45% |
| Jun 30, 2023 | -6.23% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 10.28% |
| Sep 30, 2022 | 5.98% |
| Jun 30, 2022 | 5.38% |
| Mar 31, 2022 | -12.74% |
| Dec 31, 2021 | 12.70% |
| Sep 30, 2021 | 15.43% |